Health & Wellness

Bharat Biotech Gets DGCI Nod For Intranasal COVID-19 Boosters

BP World Bureau | Jan 28 2022 03:00:08 PM
Image credits: Twitter

NEW DELHI: Drugs Controller General of India (DCGI) gave its permission to Bharat Biotech for conducting trials of intranasal booster doses against the COVID-19.
Vaccines against the novel Coronavirus disease (COVID-19) is given through injections.
Bharat Biotech's vaccine is Covaxin. It was recently granted regular market approval for use in the adult population subject to certain conditions along with Covishield by SII (Serum Institute of India).

Read: Are Children Getting More Affected By COVID-19 During Third Wave? 

India has been reporting record number of new COVID-19 cases after the Omicron variant emergence with 2,51,209 new cases and 627 deaths due to the disease.
There are 4,06,22,709 cases of the disease in the country. Out of them, 21,05,611 are active cases, 3,80,24,771 people recovered and 4,92,327 people died.